Analysis of the DYSF mutational spectrum in a large cohort of patients

Archive ouverte

Krahn, Martin | Béroud, Christophe | Labelle, Véronique | Nguyen, Karine | Bernard, Rafaelle | Bassez, Guillaume | Figarella-Branger, Dominique | Fernandez, Carla | Bouvenot, Julien | Richard, Isabelle | Ollagnon-Roman, Elisabeth | Bevilacqua, Jorge A | Salvo, Eric | Attarian, Shahram | Chapon, Françoise | Pellissier, Jean | Pouget, Jean | Hammouda, El Hadi | Laforet, Pascal | Urtizberea, Jon Andoni | Eymard, Bruno | Leturcq, France | Lévy, Nicolas

Edité par CCSD ; Wiley -

International audience. Dysferlinopathies belong to the heterogeneous group of autosomal recessive muscular dystrophies. Mutations in the gene encoding dysferlin (DYSF) lead to distinct phenotypes, mainly Limb Girdle Muscular Dystrophy type 2B (LGMD2B) and Miyoshi myopathy (MM). Here, we analysed the mutational data from the largest cohort described to date, a cohort of 134 patients, included based on clinical suspicion of primary dysferlinopathy and/or dysferlin protein deficiency identified on muscle biopsy samples. Data were compiled from 38 patients previously screened for mutations in our laboratory (Nguyen, et al., 2005; Nguyen, et al., 2007), and 96 supplementary patients screened for DYSF mutations using genomic DHPLC analysis, and subsequent sequencing of detected variants, in a routine diagnostic setting. In 89 (66%) out of 134 patients, molecular analysis identified two disease causing mutations, confirming the diagnosis of primary Dysferlinopathy on a genetic basis. Furthermore, one mutation was identified in 30 patients, without identification of a second deleterious allele. We are currently developing complementary analysis for patients in whom only one or no disease-causing allele could be identified using the genomic screening procedure. Altogether, 64 novel mutations have been identified in this cohort, which corresponds to approximately 25% of all DYSF mutations reported to date. The mutational spectrum of this cohort significantly shows a higher proportion of nonsense mutations, but a lower proportion of deleterious missense changes as compared to previous series. (c) 2008 Wiley-Liss, Inc.

Suggestions

Du même auteur

Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies

Archive ouverte | Nguyen, Karine | CCSD

International audience. DYSF encoding dysferlin is mutated in Miyoshi myopathy and Limb-Girdle Muscular Dystrophy type 2B, the two main phenotypes recognized in dysferlinopathies. Dysferlin deficiency in muscle is t...

Convergence of patient- and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy

Archive ouverte | Sanson, Benoît | CCSD

International audience. Facioscapulohumeral muscular dystrophy (FSHD) is among the most prevalent muscular dystrophies and currently has no treatment. Clinical and genetic heterogeneity are the main challenges to a ...

Deciphering the complexity of the 4q and 10q subtelomeres by molecular combing in healthy individuals and patients with facioscapulohumeral dystrophy

Archive ouverte | Nguyen, Karine | CCSD

International audience. BACKGROUND: Subtelomeres are variable regions between telomeres and chromosomal-specific regions. One of the most studied pathologies linked to subtelomeric imbalance is facioscapulohumeral d...

Chargement des enrichissements...